In the Middle East and North Africa, cancer is growing at an alarming rate, and – as Economist Impact notes – the region is on the cusp of a demographic transition, with UNICEF predicting t
At Frontiers Health 2023, a panel will look a
In an industry growing as quickly as cell therapy, keeping up with the demands of manufacturing and treatment is a challenge for the whole industry to tackle together, including stakeholder
A trade organisation representing pharma manufacturers in Europe has said plans to restrict the use of fluorinated substances known as PFAS could make manufacturing “grind
MSD has been granted a priority review by the FDA for its pulmonary arterial hypertension (PAH) candidate sotatercept, setting up a decision on the would-be blockbuster by
Views & Analysis
White Papers & Webinar
Podcasts & Video
CRISPR-based therapies are undergoing a remarkable evolution, with drug developers striving to enhance the safety, precision and efficacy of their products.
CRISPR represents the next frontier in the cell and gene therapy landscape.
Behind regulatory milestones like the recent accelerated FDA approval for Duchenne Muscular Dystrophy, robust and detailed analytics are the cornerstone of gene therapy development.
Molecular glue development continues to gain exponential momentum, with advances in screening tools, identification assays and structure-based design.
The mRNA Assay Development Summit is the first and only meeting to address the specific technical challenges of analytical, bioanalytical and potency assay development.